Hansoh Pharmaceutical and Roche Strike Strategic ADC Collaboration Worth Over $15 Billion

On October 19, 2026, Hansoh Pharmaceutical announced a strategic collaboration and license agreement with Roche covering a portfolio of antibody-drug conjugate (ADC) programs. Under the deal, Hansoh will receive a $400 million upfront payment and a $110 million one-year anniversary payment, plus potential milestone payments exceeding $15 billion tied to development, regulatory and commercialization progress, along with tiered royalties on future product sales.